Anhui Xinbeika Phase II Sewage Treatment Project Completed Completion Acceptance
Release time:
2021-10-21
30 days, meeting the contract requirements for 15 consecutive days, and stably meeting the standards for wastewater discharge. This represents the completion and acceptance of the second phase of Anhui Xinbeika sewage treatment project, and also represents that the environmental protection improvement work of Xinbeika has entered a new stage. With the continuous strengthening of environmental protection policies, a perfect environmental protection treatment system is the foundation of enterprise survival and the cornerstone of enterprise development. Starting from
2018, Anhui Xinbeika started to comprehensively improve the environmental protection treatment system in view of the bottleneck problems of environmental protection treatment such as waste gas treatment, high-salt wastewater treatment and high-concentration wastewater treatment, in the same year, the technical renovation of the regenerative high temperature oxidation furnace (RTO ) with waste gas treatment capacity of 20000 m3/h air volume was completed to ensure that the online automatic monitoring data of VOCs of the total exhaust pipe of the process tail gas reached the standard stably. The sewage treatment system was reformed to increase the wastewater treatment capacity from 60t/d to 150t/d , solve the production bottleneck problem that wastewater could not be treated in time at that time. In 2020 , the double-effect evaporation system with high-salt wastewater treatment capacity 4 t/h will be put into operation to replace the kettle steaming system with high energy consumption, low efficiency and large waste production, which cannot meet the production requirements, and the balance will be designed to prepare for the high-salt wastewater to be produced in the second phase of the production project; the halogen-containing waste gas treatment capacity 5000 m3/h activated carbon adsorption desorption system has been debugged and operated to ensure that the halogen-containing tail gas that cannot enter the RTO treatment system is stably discharged up to the standard. Due to the upgrading of wastewater pipe standards and the construction of the second-phase production project, Anhui Xinbeika has carried out overall transformation and upgrading on the basis of the existing sewage treatment system. The second-phase sewage treatment project has been constructed to increase the wastewater treatment capacity to
300m 3/d, and the ultraviolet catalytic advanced oxidation system (UV-AOP ) imported from Germany has been introduced, different from the traditional Fenton oxidation system, it has strong treatment capacity for all kinds of high-concentration wastewater, and can be well compatible with the complexity of the first and second phases of production of high-concentration wastewater in Anhui Xinbei Card. The second phase of sewage treatment project was completed, commissioned and accepted in 2021 and put into operation in 8 . So far, Anhui Xinbeika environmental protection treatment system can deal with waste gas and waste water generated by various production, effectively ensuring the safety and normal production of enterprises. (Zhou Xiang)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31